BDBM108111 US8598206, Table 6, 20

SMILES NC(=N)c1ccc(CNC(=O)[C@H](CCC2CCNCC2)NC(=O)[C@H](NS(=O)(=O)Cc2ccccc2)c2ccccc2)cc1

InChI Key InChIKey=BQJXMSPBOZFQJJ-URLMMPGGSA-N

Data  6 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 108111   

TargetPlasminogen(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108111(US8598206, Table 6, 20)
Affinity DataKi:  2.20nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetPlasma kallikrein(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108111(US8598206, Table 6, 20)
Affinity DataKi:  20nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetVitamin K-dependent protein C(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108111(US8598206, Table 6, 20)
Affinity DataKi:  210nMAssay Description:Inhibition of human aPC was determined by the method described in [0092]-[0098] using human activated protein C from Enzyme Research Laboratories at ...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCoagulation factor XI(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108111(US8598206, Table 6, 20)
Affinity DataKi:  1.00E+3nMAssay Description:Inhibition of human FXIa was determined by the method described in [0092]-[0098] using activated human Factor XI from Enzyme Research Laboratories at...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCoagulation factor X(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108111(US8598206, Table 6, 20)
Affinity DataKi:  1.60E+3nMAssay Description:Inhibition of human FXa was determined by the method described in [0092]-[0098] using activated human Factor X from Enzyme Research Laboratories at 5...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetTranscription initiation factor IIA subunit 1(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108111(US8598206, Table 6, 20)
Affinity DataKi:  1.70E+3nMAssay Description:Inhibition of human FIIa was determined by the method described in [0092]-[0098] using human alpha-thrombin from Enzyme Research Laboratories at 0.1 ...More data for this Ligand-Target Pair
In DepthDetails US Patent